Cleveland BioLabs' scientists are working hard to develop drugs that help healthy cells stay that way, as well as drugs that promote cell death in cancerous tumors. The company has based its research on the suppression and stimulation of the process known as apoptosis, a form of cell-death that occurs after exposure to radiation, toxic chemicals, or internal stresses. In development are two product lines: protectans (suppressing apoptosis in healthy cells after radiation exposure) and curaxins (stimulating apoptosis in some forms of cancer). Protectans have applications in reducing side effects from cancer treatment and terrorist or nuclear events, while curaxins are being developed as anticancer therapies.